Interleukin-1 (IL-1) and IL-1 receptors are constitutively expressed in normal brain. IL-1 increases non-rapid eye movements (NREM) sleep in several animal species, an effect mediated in part by interactions with the serotonergic system. The site(s) in brain at which interactions between IL-1 and the serotonergic system increase NREM sleep remain to be identi®ed. The dorsal raphe (DRN) is the origin of the major ascending serotonergic pathways to the forebrain, and it contains IL-1 receptors. This study examined the hypothesis that IL-1 increases NREM sleep by acting at the level of the DRN. IL-1b (0.25 and 0.5 ng) was microinjected into the DRN of freely behaving rats and subsequent effects on sleep±wake activity were determined. IL-1b 0.5 ng increased NREM sleep during the ®rst 2 h post-injection from 33.5 AE 3.7% after vehicle microinjection to 42.9 AE 3.0% of recording time. To determine the effects of IL-1b on electrophysiological properties of DRN serotonergic neurons, intracellular recordings were performed in a guinea-pig brain stem slice preparation. In 26 of 32 physiologically and pharmacologically identi®ed serotonergic neurons, IL-1b superfusion (25 ng/mL) decreased spontaneous ®ring rates by 50%, from 1.6 AE 0.2 Hz (before IL-1b superfusion) to 0.8 AE 0.2 Hz. This effect was reversible upon washout. These results show that IL-1b increases NREM sleep when administered directly into the DRN. Serotonin enhances wakefulness and these novel data also suggest that IL-1b-induced enhancement of NREM sleep could be due in part to the inhibition of DRN serotonergic neurons.
Introduction
Although interleukin-1 (IL-1) was originally described as a product of the peripheral immune system, there is now ample evidence that IL-1, IL-1 receptors and the IL-1 receptor antagonist are constitutively expressed in normal brain (Vitkovic et al., 2000) . IL-1 modulates behaviours such as feeding, sexual behaviour, social exploration, locomotor activity and sleep . IL-1 consistently has been shown to enhance non-rapid eye movement (NREM) sleep and inhibit rapid eye movement (REM) sleep in several animal species (Terao et al., 1998; Krueger & Fang, 2000) . Moreover, central administration of the IL-1 receptor antagonist or of antibodies directed against IL-1 reduces spontaneous NREM sleep in normal animals and inhibits the physiological NREM sleep rebound that follows sleep deprivation (Opp & Krueger, 1994a, b) . IL-1 mRNA expression in rat brain exhibits diurnal variation with greater levels during the light (rest/sleep) period than during the dark (active) period (Taishi et al., 1997) and increases during sleep deprivation (Mackiewicz et al., 1996) . IL-1 is detected more frequently in plasma samples taken from humans during sleep than during waking (Gudewill et al., 1992) . IL-1-like activity in cerebrospinal¯uid of cats varies in phase with the sleep±wake cycle (Lue et al., 1988) and IL-1 plasma levels in humans peak at sleep onset (Moldofsky et al., 1986) .
Extensive experimental data and clinical observations indicate that brain serotonin (5-hydroxytryptamine; 5-HT) plays a pivotal role in the regulation of many physiological processes and complex behaviours (Jacobs & Azmitia, 1992) , including waking and sleep (Jouvet, 1999; Pace-Schott & Hobson, 2002) . Speci®cally, it has been proposed that 5-HT released during wakefulness promotes wakefulness per se, and triggers subsequent sleep via sleep-inducing factor(s) (Jouvet et al., 1983; Jouvet, 1999) .
The IL-1 and serotonergic systems in¯uence each other and exhibit a wide range of overlapping biological activities (Imeri & De Simoni, 1999) . IL-1 stimulates 5-HT release in the hypothalamus (Gemma et al., 1997) and other brain areas (Imeri & De Simoni, 1999 ). An intact brain serotonergic system is necessary for the full manifestation of IL-1 effects on NREM sleep. Depletion of brain 5-HT or blockade of 5-HT2 receptors antagonizes part of IL-1-induced enhancement of NREM sleep. Collectively, these data suggest that IL-1 effects on NREM sleep are mediated, in part, by the serotonergic system (Imeri & De Simoni, 1999) .
As IL-1 microinjected into several brain regions (extending from the brain stem to the diencephalon) does not enhance NREM sleep (Walter et al., 1989) , the site(s) in brain where IL-1 acts to enhance NREM sleep remain to be identi®ed. Observations that IL-1 increases NREM sleep in part through the serotonergic system suggest a neurochemical substrate that might mediate IL-1 effects on NREM sleep. Because the dorsal raphe nucleus (DRN) is the origin of the major ascending serotonergic pathways to the forebrain (Jacobs & Azmitia, 1992) and it contains IL-1 receptors (Cunningham & De Souza, 1993; Scho Èbitz et al., 1994) , the same observations also suggest that the DRN might represent one brain region that mediates IL-1 effects on NREM sleep.
The present study tested two distinct, yet related hypotheses. First, to test the hypothesis that the DRN represents one brain region where IL-1 acts to enhance NREM sleep, IL-1b was microinjected into the DRN of freely behaving rats and subsequent sleep±wake activity was quanti®ed. Second, to test the hypothesis that the activity of DRN serotonergic neurons is modi®ed by IL-1b, intracellular recordings were obtained from physiologically and pharmacologically identi®ed DRN serotonergic neurons using a guinea-pig brain stem slice preparation and changes induced by IL-1b in ®ring rate and membrane potential were determined.
Materials and methods

Substances
IL-1b (human recombinant IL-1b expressed in Escherichia coli) was purchased from R & D System (Minneapolis, MN, USA). Lyophilized IL-1b was dissolved in pyrogen-free saline containing 0.1% bovine serum albumin, aliquoted, frozen and stored at À80 8C until used. Serotonin and noradrenaline (NA; Sigma, St Louis, MO, USA) used in the in vitro experiments were dissolved just prior to use in arti®cial cerebrospinal¯uid (ACSF) of the following composition (mM): NaCl 120, KCl 2.5, KH 2 PO 4 1.25, NaH 2 PO 4 1.25, NaHCO 3 22, MgSO 4 2, CaCl 2 2, glucose 10 (®nal pH 7.35) and applied via bath perfusion.
In vivo experiments
Animals
Male Sprague±Dawley rats (225±275 g at the time of surgery, Charles River, Calco CO, Italy) were anaesthetized (pentobarbital sodium 40 mg/kg chloral hydrate 180 mg/kg, intraperitoneally), positioned in a stereotaxic apparatus and surgically prepared for chronic polygraphic recordings. Stainless steel screws served as electroencephalographic (EEG) and ground electrodes after placement over frontal, parietal and occipital cortices. Te¯on-coated silver wires were inserted in the neck muscles to record electromyographic activity. A calibrated 30-kV thermistor (Omega Engineering, Stamford, CT, USA) was implanted between the dura mater and the skull over the parietal cortex to monitor cortical brain temperature (T cort ). A stainless steel guide cannula (length, 1.5 cm; outer diameter, 0.5 mm) was stereotaxically placed 3 mm above the DRN. In order to avoid damage to the midline sinus or to the Sylvius aqueduct, cannulae were implanted at a 308 angle to the sagittal plane. The following stereotaxic coordinates (adapted from Paxinos & Watson, 1986) were used: anterioposterior, 0.7 mm from interaural line; lateral, 3.3 mm; dorsoventral, 3.6 mm below the dura mater (tooth bar, À3.3 mm). Insulated leads were routed from the screws, the electromyographic electrodes, and the thermistor to a Te¯on pedestal (Plastics One Inc., Roanoke, VA, USA) that was cemented in place with dental acrylic (Isocryl; Lang Dental Supply, Wheeling, IL, USA). The incision was treated topically with polysporin (polymixin B sulphate ± bacitracin zinc) and the animals were placed under heat lamps and monitored until recovery from anaesthesia. On the third postsurgical day, the rats were connected to the recording apparatus (see later) via a¯exible tether (connected to the Te¯on pedestal) that allowed relatively unrestricted movement within the cage. For the next 5 days the animals were allowed to adapt to the experimental procedures before the experiments began. Rats were always housed individually in environmentally controlled chambers, maintained at 22 AE 1 8C with a 12 : 12 h light±dark cycle. Food and water were available ad libitum. Rats were fed a standard rat maintenance diet (Mucedola SRL, Settimo Milanese MI, Italy 
Apparatus and recording
Signals from the EEG and electromyographic electrodes as well as from the thermistor were fed into a Grass (Quincy, MA, USA) polygraph in the adjacent room. The EEG was ampli®ed (factor of 3000) and analog bandpass ®ltered between 0.1 and 40 Hz (frequency response, AE3 dB; ®lter frequency roll off, 12 dB/octave). These conditioned signals were digitized with 12-bit precision at a sampling rate of 128 Hz (AT-MIO-64F5; National Instruments, Austin, TX, USA). The digitized EEG waveform, the T cort samples, and integrated values for EMG activity were stored as binary computer ®les until subsequent analyses. Post-acquisition determination of vigilance state was done by visual scoring of 12-s epochs using custom-written software. The animal's behaviour was classi®ed as wakefulness, NREM or REM sleep. EEG power density values were obtained for each artefact-free 12-s scoring epoch for the frequency range of 0.5±20 Hz. Values in the 0.5±4.0 Hz (delta) frequency range were collapsed and integrated for 12-s epochs, and used as measures of slow wave activity (SWA). These values for SWA were then matched to corresponding 12-s epochs that had already been scored for behavioural state to obtain SWA during NREM sleep.
Experimental protocol
Each animal was injected with both vehicle (pyrogen-free saline containing 0.1% bovine serum albumin) and at least one dose of IL-1b, so each rat served as its own control. No animal received more than three microinjections, one vehicle and two IL-1b. Animals also were studied in two further conditions: after simple handling for the time required by the microinjection procedure and after sham injection, during which an injection needle was inserted, but no microinjection made. Experiments were scheduled randomly with an interval of at least 3 days between microinjections. IL-1b and vehicle were administered 15 min prior to dark onset in a constant volume of 100 nL, using a stainless steel needle (length, 1.8 cm; outer diameter, 0.3 mm), connected via polyethylene tubing to a Hamilton microsyringe and inserted through the guide cannula. The needle extended 3 mm past the tip of the guide cannula, reaching the DRN. Microinjections were performed over a 1-min period. After the microinjection the needle was left in place for 3 min. The highest IL-1b dose microinjected (0.5 ng, 29 fmol) corresponds to one-®fth of the lowest IL-1 dose that effectively enhances NREM sleep when administered intracerebroventricularly into rats Lancel et al., 1996; Imeri et al., 1997) . IL-1b and vehicle were dissolved, aliquoted and delivered using sterile procedures. Polygraphic recordings began immediately after the microinjections and continued for 12 h.
At the end of the experiments an overdose of chloral hydrate was administered and dye was microinjected (100 nL) into the microinjection site; the brains were then removed and ®xed. The position of the dye spot was determined from 40-mm-thick, frozen, neutralred-stained sections. In seven of 20 animals used in this study the histological examination of the site of injection revealed that the injecting needle was in the DRN ( Fig. 1A and B). In the remaining 13 animals the injection sites were located outside the DRN (Fig. 1A ).
Statistical analysis
One-way analysis of variance (ANOVA) was used to determine if the experimental variables measured in this study were signi®cantly different between the three control conditions tested (vehicle microinjection vs. needle insertion vs. handling). Dependent variables were: (i) amount of time spent in the different phases of the sleep±wake cycle, (ii) EEG SWA during NREM sleep, (iii) sleep architecture parameters and (iv) T cort values.`Manipulation' was the main (®xed) effect. An a level of P < 0.05 was taken to indicate a statistically signi®cant difference between conditions. One-way ANOVA was also used to determine if values obtained after administration of IL-1 deviated statistically from values obtained after vehicle microinjection. Experimental variables (see above) were the dependent variables and`manipulation' (vehicle vs. IL-1 doses) the main (®xed) effect. On the basis of visual inspection of the results, statistical analyses were conducted across 2-h time blocks. An a level of P < 0.05 was used to indicate a statistically signi®cant difference between vehicle and IL-1. If ANOVA indicated statistically signi®cant drug main effect, post hoc multiple comparisons were made using Fisher's least signi®cant difference.
In vitro experiments
Preparation of brain stem slices
Guinea-pig brain slices were chosen for this study because they have been extensively used in the electrophysiological investigation of neurons involved in the regulation of sleep±wake activity and thermoregulatory mechanisms (see, for instance, Ono et al., 1987; Shibata & Blatteis, 1991; Xin & Blatteis, 1992; Bal & McCormick, 1993; Leonard & Llinas, 1994; Alonso et al., 1996; Khateb et al., 1998) . Guinea-Pigs (Hartley strain, 150±175 g at time of experiment; Charles River, Italy) were anaesthetized with ether and decapitated. The brain then was removed rapidly and placed in ice-cold (4 8C) ACSF, continuously bubbled with an O 2 ±CO 2 mixture (95 : 5%). Coronal sections (400 mm thick) were then cut with a Vibratome 1 from a block of tissue containing the DRN in ice-cold carbogenated ACSF. Two slices were taken from each animal for subsequent in vitro recording. The slices were then incubated at room temperature in carbogenated ACSF and were left to recover for at least 1 h. Then a single slice was transferred to a submersion-type slice recording chamber, through which carbogenated ACSF prewarmed to 34 8C was continuously superfused at a rate of 2.5 mL/min. The DRN was located in the midline of the slice, between the medial longitudinal fasciculi extending dorsally towards the aqueduct. Only sections containing the midline decussating ®bres of the superior cerebellar peduncle were selected for use. Intracellular recordings were made throughout the midline and paramidline DRN.
Recording methods and electrophysiological characterization of serotonergic neurons
Neurons were impaled with glass microelectrodes pulled from 1.5-mm ®lament-containing tubing ®lled with 2 M potassium-acetate (impedance, 60±80 MV). Conventional intracellular recordings were made from DRN neurons using the bridge balance mode on an Axoclamp 2B ampli®er. The bridge was frequently checked to ensure that it was balanced throughout experiments. Serotonergic DRN neurons were identi®ed by their distinctive discharge and membrane properties (see in vitro results). Only spontaneously active neurons (about 80% of the impaled neurons) were included in the study. Neurons that did not display electrophysiological properties of serotonergic neurons (<10%) were discarded and not further analysed. Because most of the serotonergic DRN neurons display a steady discharge, without sustained pauses or bursts in ®ring, their mean membrane potential was de®ned as the membrane potential value measured in the middle of each interspike interval. All neurons that met the electrophysiological criteria described above were further characterized pharmacologically (see in vitro results).
In vitro drug application
Test substances, dissolved in warmed carbogenated ACSF just prior to use and applied via bath perfusion, as described above, arrived in the bath 2 min after application. Serotonin and NA were applied for 1 min. IL-1 was applied for 2 min. The dose of IL-1b (25 ng/mL; 1.5 nM) was chosen on the basis of previous in vitro electrophysiological studies (Miller et al., 1991; Shibata & Blatteis, 1991; Pringle et al., 1996; D'Arcangelo et al., 1997) . The effects of the different drugs were evaluated during intracellular recordings by comparing the mean neuronal discharge frequency and the membrane potential before any treatment (baseline record) and 3 min after their addition to the superfusing ACSF. All data are from neurons that showed recovery upon washout of applied substances.
Data acquisition and analysis
Signals were conditioned through an Axoclamp 2B ampli®er (Axon, Foster City, CA, USA), followed online on a paper chart recorder, and continuously acquired onto a VHS tape recorder by means of an Instrutech VR 100B analog±digital converter (Instrutech Corp., Great Neck, NY, USA). The off-line analysis of data was performed with a Macintosh computer equipped with a direct memory access board (Instrutech ITC 16, Instrutech Corp.) and Axograph 4.6 software (Axon). One-way analysis of variance and Student's t-test, when appropriate, were used to determine if the electrophysiological variables investigated differed signi®cantly between the three conditions tested (i.e. before, during and following substance application). Statistical differences were considered signi®cant at P < 0.05.
Results
In vivo results
IL-1b enhanced NREM sleep when microinjected into the DRN
NREM sleep was signi®cantly increased for 2 h after microinjection of 0.5 ng IL-1b into the DRN (n 7) from 33.5 AE 3.7% of recording time (after vehicle) to 42.9 AE 3.0% (P < 0.05; Fig. 2, Table 1 ). This increase in the amount of NREM sleep was due to a signi®cant increase in the number of NREM sleep bouts, from 17.1 AE 1.8 to 29.9 AE 3.8 (P < 0.05). EEG SWA during NREM sleep was not modi®ed at any time after microinjection of 0.5 ng IL-1b.
In the ®rst 2 h post-injection, 0.5 ng IL-1b induced a signi®cant decrease in the amount of REM sleep from 9.9 AE 1.5% of recording time to 2.9 AE 1.2% (P < 0.05; Fig. 2, Table 1 ). Amount of REM sleep was also reduced 3±4 h post-injection, from 8.2 AE 1.7% of recording time (control condition) to 1.0 AE 0.6% (Table 1) . Owing to these changes in the amount of both NREM and REM sleep, the amount of NREM sleep/total sleep per cent ratio signi®cantly increased from 77.3 AE 3.2 to 93.4 AE 2.5 (P < 0.01). In the ®rst 2 h post-injection, 0.5 ng IL-1b also induced a fragmentation of the sleep±wake cycle, with a statistically signi®cant increase in the number of transitions (from one state to another) from 79.6 AE 8.8 to 139.1 AE 15 (P < 0.01). Over the same time interval, 0.5 ng IL-1b signi®cantly increased T cort from 37.0 AE 0.1 8C (control condition) to 37.6 AE 0.1 8C (Fig. 2, Table 1 ). At 3±4 h post-injections, 0.5 ng IL-1b signi®cantly increased T cort from 37.3 AE 0.1 8C (control condition) to 37.9 AE 0.1 8C (Table 2) . At the lower dose tested in this study (0.25 ng) IL-1b did not signi®cantly affect sleep±wake activity (Fig. 2, Table 1 ), EEG SWA during NREM sleep and T cort (Fig. 2, Table 1 ).
When microinjections missed the DRN (Fig. 1) , IL-1b did not alter the amount of NREM sleep (Fig. 2, Table 1 ) or EEG SWA during NREM sleep irrespective of dose and time. However, 0.5 ng IL-1b microinjected outside the DRN signi®cantly reduced REM sleep 1±2 h post-injection (from 11.2 AE 1.6% after vehicle to 5.6 AE 1.5% of recording time, P < 0.05; Fig. 2 , Table 1 ) and 3±4 h post-injection (from 7.9 AE 1.1 to 3.7 AE 1.2%, P < 0.05; Table 1 ). The reduction in amoutn of REM sleep was due to a signi®cant decrease in mean duration of REM bouts (from 1.7 AE 0.2 min to 1.0 AE 0.4 min; P < 0.05). T cort was not altered by IL-1b during any of the post-injection time blocks (Fig. 2 , Table 1 ). The lower IL-1b dose tested did not induce any signi®cant change in sleep±wake activity (Fig. 2, Table 1 ), EEG SWA during NREM sleep and T cort (Fig. 2, Table 1 ).
Sham injection or vehicle microinjection into and outside the DRN did not alter sleep±wake behaviour and T cort
Values for experimental variables did not differ between the three control conditions tested (see above, Materials and methods ± Experimental protocol), irrespective of whether the microinjection sites were located inside or outside the DRN (Table 2 ). The amount of time the rats spent in different vigilance states is consistent with values previously reported during control conditions for Sprague±Dawley rats during the dark phase of the light±dark cycle (Opp, 1997) .
In vitro results
Serotonergic neurons in the DRN were inhibited by 5-HT and excited by NA Thirty-®ve spontaneously active neurons were electrophysiologically characterized as serotonergic on the basis of their distinctive discharge and membrane properties (Williams et al., 1988) : slow and regular ®ring rate (range, 0.5±4 Hz; Fig. 3A ), large after-hyperpolarization (9± 20 mV; Fig. 3A and B) , high input resistance (150±400 MV), long spike duration (1.5±2.5 ms; Fig. 3B ). Because serotonergic neurons have been shown to be inhibited by 5-HT and stimulated by NA (Baraban et al., 1978; Vandermaelen & Aghajanian, 1983; Yoshimura & Higashi, 1985; Williams et al., 1988) , electrophysiologically identi®ed neurons were further characterized pharmacologically. Following 5-HT perfusion, 32 of the 35 neurons either ceased ®ring (Fig. 3C) or their ®ring rate was signi®cantly reduced. This reduction in ®ring rates from 1.4 AE 0.3 Hz before 5-HT perfusion to 0.2 AE 0.1 Hz during 5-HT perfusion (P < 0.001) was associated with membrane hyperpolarizations ranging from À2 to À14 mV, with a mean value of À6.4 AE 1 mV (from À54.2 AE 1.9 mV before 5-HT perfusion to À60.6 AE 2.3 mV during 5-HT perfusion, P < 0.001). These effects were fully reversible: within 5 min after cessation of tissue exposure to 5-HT, ®ring rate and membrane potential returned to 1.2 AE 0.2 Hz and 54.9 AE 2.1 mV, respectively. The three neurons that were not inhibited by 5-HT were not further analysed. In 13 neurons, following IL-1b perfusion and full wash-out, perfusion with NA 30 mM increased the ®ring rate from a baseline value of 1.5 AE 0.3 Hz to 3.6 AE 0.5 Hz (P < 0.001; Fig. 3D ). This effect was associated with a mean depolarization of 1.9 AE 0.6 mV (from a resting membrane potential value of À54.9 AE 2.1 mV before NA perfusion to À53.0 AE 2 mV during NA perfusion; P < 0.05). NA effects were fully reversible. The electrophysiological and neuropharmacological criteria used for the identi®cation of DRN serotonergic neurons, ®rst developed in rats, proved to be valid and reliable when used in guineapigs, for in vivo and in vitro extra-and intracellular elctrophysiological recordings (Craven et al., 1994 (Craven et al., , 2001 Mundey et al., 1994; Conley et al., 2002) .
IL-1b inhibited serotonergic DRN neurons
Twenty-six (81%) of 32 presumed serotonergic DRN neurons were inhibited by bath application of IL-1 (25 ng/mL, Fig. 4) . IL-1b perfusion induced in these 26 neurons a signi®cant decrease in spontaneous ®ring rate, from 1.6 AE 0.2 Hz in control conditions to 0.8 AE 0.2 Hz during IL-1b perfusion. After wash-out, the ®ring rate returned to 1.6 AE 0.3 Hz. The IL-1b-induced reduction in ®ring rate was associated with a non-signi®cant membrane hyperpolarization. Three neurons were not responsive to IL-1b. Three neurons were inhibited by IL-1b, but data from these neurons were not analysed as the effect was not washable. None of the 32 neurons studied was depolarized or its spontaneous ®ring was increased by IL-1b perfusion.
Discussion
The results of the present study show that IL-1b, when microinjected into the DRN (but not into adjacent brain stem areas) of freely behaving rats enhances NREM sleep. Furthermore, IL-1b inhibits the ®ring rates of physiologically and pharmacologically identi®ed DRN serotonergic neurons in brain slice preparations. Collectively, these results suggest that IL-1b may increase NREM sleep by acting at the level of the DRN, perhaps due to the inhibition of DRN serotonergic neurons.
IL-1b can enhance NREM sleep by acting at the level of the DRN Speci®c brain areas at which IL-1 can act to enhance NREM sleep remain to be fully identi®ed, although there have been some studies to address this question. A puri®ed IL-1 preparation obtained from stimulated human monocytes failed to enhance NREM sleep when microinjected into several areas of the rabbit brain, extending from the brain stem to the diencephalon and including areas in the rostral medulla, pons and midbrain, the hypothalamic preoptic area and basal forebrain, the posterior hypothalamus (Walter et al., 1989) . Recent evidence suggests that IL-1 may alter NREM sleep by actions on the preoptic/anterior hypothalamic area; IL-1 increases ®ring rates of neurons active during NREM sleep and reduces ®ring rates of neurons active during waking (Alam et al., 2001) . Consistent with these results are recent observations that IL-1 increases cytosolic Ca 2 in cultured hypothalamic neurons (De et al., 2002) . IL-1, when microinjected into the rat locus coeruleus, potentiates EEG frequencies in the 3±9 Hz range and enhances sleep [as de®ned on the basis of visual inspection of the animal behaviour (De Sarro et al., 1997) ]. By contrast, IL-1 induces wakefulness when microinjected into the rat hypothalamic paraventricular nucleus (Slisli & de Beaurepaire, 1999) . As IL-1 stimulates the release of corticotropin-releasing hormone (Barbanel et al., 1990) , this latter effect is likely to be due to the increased levels of this peptide, which enhances wakefulness (Chang & Opp, 2001) .
The involvement of both IL-1 and 5-HT in sleep regulation, as well as growing evidence showing that IL-1-induced enhancement of NREM sleep is mediated, in part, by the serotonergic system, are rewieved in the Introduction. The DRN is the origin of the major ascending serotonergic pathways to the forebrain (Jacobs & Azmitia, 1992) and it contains IL-1 receptors (Cunningham & De Souza, 1993; Scho Èbitz et al., 1994) . Therefore, the results of the present study, by demonstrating for the ®rst time that IL-1b enhances polygraphically de®ned NREM sleep when microinjected into the DRN of conscious animals, indicate that the DRN might represent one brain region where IL-1 can affect the serotonergic system and, moreover, one brain region that mediates IL-1 effects on NREM sleep.
IL-1b inhibits DRN serotonergic neurons
Results in the present paper are the ®rst to provide electrophysiological evidence that in brain slices IL-1b inhibits physiologically and pharmacologically identi®ed DRN serotonergic neurons. As 5-HT is a wake-promoting agent (Jouvet, 1999; Pace-Schott & Hobson, 2002) , data in the present paper suggest that the increase in NREM sleep induced by IL-1b microinjection into the DRN can result, in part, from the inhibition of DRN serotonergic neurons.
Serotonin, which promotes wakefulness per se, also has been proposed to induce the synthesis and/or release of factor(s) that subsequently enhance sleep (Jouvet et al., 1983; Jouvet, 1999) . Recent data directly support a dual role for 5-HT in sleep regulation. Increasing serotonergic activity by injecting rats with the 5-HT precursor 5-hydroxytryptophan (5-HTP) ®rst enhances wakefulness and later increases NREM sleep (Imeri et al., 2000) .
The hypothalamic preoptic area and basal forebrain play a crucial role in the regulation of NREM sleep (reviewed in Jones, 2000; McGinty & Szymusiak, 2000; Saper et al., 2001) . IL-1 releases 5-HT from axon terminals in the hypothalamus (Shintani et al., 1993) , suggesting that IL-1 could promote NREM sleep not only by inhibiting wake-promoting DRN serotonergic neurons, but also by enhancing axonal 5-HT release in speci®c brain areas. The anterior hypothalamus is the only brain area where stimulation of serotonergic activity can restore physiological sleep in cats that have been made insomniac by brain 5-HT depletion (Denoyer et al., 1989) . Serotonin hyperpolarizes basal forebrain cholinergic neurons responsible for cortical activation (Khateb et al., 1993) . Furthermore, because 5-HT induces IL-1 both in vitro (Silverman et al., 1989) and in vivo (Gemma et al., 2003) , it could amplify the effects of exogenously administered IL-1. These ®ndings would explain previous results showing that 5-HT is necessary for the full manifestation of IL-1 effects on NREM sleep (reviewed in Imeri & De Simoni, 1999) . In summary, IL-1-induced NREM sleep enhancement could result from both the inhibition of the serotonergic cell bodies and the enhancement of 5-HT release from axon terminals in speci®c brain regions involved in NREM sleep generation. These effects may occur at different time points after IL-1 is administered or released in physiological or pathological conditions. They may also depend on sites in brain accessed by IL-1.
IL-1b-induced inhibition of REM sleep is not mediated by DRN serotonergic neurons
The ®ring rate of DRN serotonergic neurons and 5-HT release from axon terminals are state-dependent: they are maximal during wakefulness, reduced during NREM sleep and suppressed (or minimal) during REM sleep (McGinty & Harper, 1976; Trulson & Jacobs, 1979; Cespuglio et al., 1981 Cespuglio et al., , 1990 Lydic et al., 1987; Wilkinson et al., 1991; Imeri et al., 1994; Portas & McCarley, 1994) . The observation that inhibition of the serotonergic system results in the enhancement of REM sleep (Adrien, 1995) suggests that suppressed serotonergic activity is permissive for REM sleep generation (Steriade & McCarley, 1990; Pace-Schott & Hobson, 2002) . In vitro results of the present study indicate that IL-1b signi®cantly reduces, but does not suppress, the ®ring rate of DRN neurons. In vivo results indicate that IL-1b microinjection into the DRN and adjacent brain stem areas does not increase, but rather inhibits, REM sleep. Taken together, these observations suggest that a reduced serotonergic activity is not suf®cient to permit REM sleep, which could be enhanced only when serotonergic activity is abolished. Moreover, REM sleep is inhibited also by the noradrenergic neurons of the locus coeruleus (Pace-Schott & Hobson, 2002), which were not targeted in this study.
Observations that blockade of 5-HT2 receptors does not modify IL-1-induced inhibition of REM sleep suggests that IL-1 inhibitory effects on REM sleep are not mediated by the serotonergic system (or at least not through this receptor subtype), but by other neurochemical systems. The possible spreading of IL-1 into adjacent cholinergic structures of the pontine tegmentum from microinjection sites within and outside the DRN cannot be ruled out. As the cholinergic system is involved in the generation of REM sleep (Steriade & McCarley, 1990; Semba, 1999; Baghdoyan, 1997) and IL-1 inhibits ACh release in vivo in the hippocampus (Rada et al., 1991) , as well as IL-1 synthesis in cultured pituitary cells (Carmeliet et al., 1989) , IL-1 action on the cholinergic structures of the pontine tegmentum might account for the inhibition of REM sleep described in the present paper.
IL-1b-induced inhibition of DRN serotonergic neurons can increase brain cortical temperature IL-1b administration into the DRN nucleus induces a transient and moderate increase in T cort . The typical response to IL-1 administration through several routes includes an increase in NREM sleep and a febrile response [reviewed in Terao et al., 1998; Krueger & Fang, 2000) . Although it is well established that, under certain circumstances, increases in body and brain temperature promote NREM sleep (reviewed in McGinty & Szymusiak, 1990 ), an extensive literature shows that NREM sleep enhancement induced by IL-1 is a speci®c effect and it is not merely a byproduct of fever, because it occurs also when febrile response is blocked (Krueger et al., 1984; Opp et al., 1989) .
Observations that IL-1b increases T cort when microinjected into the DRN, whereas no changes in T cort are observed when IL-1 is microinjected into brain stem areas surrounding the DRN, suggest that this IL-1b effect is due to speci®c actions on the DRN. Whereas the ®ring rate of serotonergic DRN neurons is not affected by the peripheral administration of synthetic muramyl dipeptide, an analogue of Grampositive bacterial cell wall component (Fornal et al., 1987) , the present data show that DRN serotonergic neurons are inhibited by direct IL-1b administration.
Although the role of 5-HT in thermoregulation is complex, there is evidence that under certain conditions 5-HT may lower body/brain temperature, as 5-HT excites hypothalamic warm-sensitive neurons, inhibits cold-sensitive neurons and stimulates the release of proopiomelanocortin-derived peptides, including a-melanocyte-stimulating hormone, whose hypothermic effect is well established (reviewed in Imeri et al., 2000) . Observation that serotonergic activation induced by the administration of the 5-HT precursor 5-HTP decreases brain temperature (Imeri et al., 2000) supports such a role for 5-HT. The present results, showing that IL-1 inhibits DRN serotonergic neurons in brain slices and increases T cort when microinjected into the DRN of freely behaving animals, are in agreement with the hypothesis that 5-HT lowers body/brain temperature and might explain the increase in T cort observed following IL-1 microinjection into the DRN.
In conclusion, the results presented here demonstrate for the ®rst time that IL-1b enhances NREM sleep when microinjected into the DRN of conscious animals and inhibits the ®ring rates of DRN serotonergic neurons in a slice preparation. These data suggest that the DRN may be one speci®c brain region where IL-1b inhibits the wakepromoting serotonergic system, with subsequent enhancement of NREM sleep.
